Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Asset Writedowns and Impairment (2016 - 2025)

Angiodynamics (ANGO) has disclosed Asset Writedowns and Impairment for 16 consecutive years, with -$100000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 52.61% year-over-year to -$100000.0, compared with a TTM value of -$13000.0 through Nov 2025, up 99.99%, and an annual FY2025 reading of $173000.0, down 80.09% over the prior year.
  • Asset Writedowns and Impairment was -$100000.0 for Q4 2025 at Angiodynamics, down from -$27000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $3.4 million in Q1 2024 and bottomed at -$158.6 million in Q2 2024.
  • Average Asset Writedowns and Impairment over 5 years is -$8.1 million, with a median of -$14000.0 recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment crashed 273.33% in 2023, then skyrocketed 4008.05% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at -$14000.0 in 2021, then surged by 400.0% to $42000.0 in 2022, then surged by 2154.76% to $947000.0 in 2023, then crashed by 122.28% to -$211000.0 in 2024, then skyrocketed by 52.61% to -$100000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for ANGO at -$100000.0 in Q4 2025, -$27000.0 in Q3 2025, and $173000.0 in Q2 2025.